Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Tong, C. Dávila-Fajardo, A. Borobia, L. Martínez-González, R. Lubomirov, Laura León, M. Bañares, X. Díaz-Villamarín, C. Fernández‐Capitán, J. Barrera, A. Carcas (2016)
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish PopulationPLoS ONE, 11
M. Pirmohamed, G. Burnside, N. Eriksson (2014)
A Randomized Trial of Genotype-Guided Dosing of Warfarin
V. Manolopoulos, G. Ragia, A. Tavridou (2010)
Pharmacogenetics of coumarinic oral anticoagulants.Pharmacogenomics, 11 4
E. Wypasek, A. Branicka, M. Awsiuk, J. Sadowski, A. Undas (2014)
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.Thrombosis research, 134 3
G. Ragia, V. Kolovou, G. Kolovou, S. Konstantinides, E. Maltezos, A. Tavridou, D. Tziakas, A. Zee, V. Manolopoulos (2017)
A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.Pharmacogenomics, 18 1
R. Saraeva, I. Paskaleva, E. Doncheva, C. Eap, V. Ganev (2007)
Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirementsJournal of Clinical Pharmacy and Therapeutics, 32
D. Sychev, A. Rozhkov, R. Kazakov, A. Ananichuk (2016)
The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillationDrug Metabolism and Personalized Therapy, 31
J. Cerezo-Manchado, V. Roldán, J. Corral, M. Rosafalco, A. Antón, J. Padilla, V. Vicente, R. González-Conejero (2016)
Genotype-guided therapy improves initial acenocoumarol dosingThrombosis and Haemostasis, 115
R. Howard, J. Leathart, D. French, E. Krishan, Hugo Kohnke, M. Wadelius, R. Schie, T. Verhoef, A. Zee, A. Daly, R. Barallon (2011)
Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes.Clinica chimica acta; international journal of clinical chemistry, 412 23-24
F. Smires, Caroline Moreau, R. Habbal, Virginie Siguret, S. Fadili, Jean-Louis Golmard, A. Assaidi, Philippe Beaune, M. Loriot, S. Nadifi (2012)
Influence of genetics and non‐genetic factors on acenocoumarol maintenance dose requirement in Moroccan patientsJournal of Clinical Pharmacy and Therapeutics, 37
J. Cerezo-Manchado, M. Rosafalco, A. Antón, V. Pérez-Andreu, N. García-Barberá, A. Martínez, J. Corral, V. Vicente, R. González-Conejero, V. Roldán (2012)
Creating a genotype-based dosing algorithm for acenocoumarol steady doseThrombosis and Haemostasis, 109
L. Bodin, C. Verstuyft, D. Tregouet, A. Robert, L. Dubert, C. Funck-Brentano, P. Jaillon, P. Beaune, P. Laurent-Puig, L. Becquemont, M. Loriot (2005)
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood, 106 1
M. Pirmohamed, F. Kamali, A. Daly, M. Wadelius (2015)
Oral anticoagulation: a critique of recent advances and controversies.Trends in pharmacological sciences, 36 3
J. Nastasi-Catanese, J. Padilla-Gutiérrez, Y. Valle, F. Ortega-Gutiérrez, M. Gallegos-Arreola, Luis Figuera (2013)
Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response.Genetics and molecular research : GMR, 12 4
S. Rathore, S. Agarwal, S. Pande, S. Singh, T. Mittal, B. Mittal (2012)
Therapeutic Dosing of Acenocoumarol: Proposal of a Population Specific Pharmacogenetic Dosing Algorithm and Its Validation in North IndiansPLoS ONE, 7
D. Kumar, D. Shewade, M. Loriot, P. Beaune, B. Chandran, J. Balachander, C. Adithan (2014)
An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) populationEuropean Journal of Clinical Pharmacology, 71
E. Jiménez-Varo, M. Cañadas-Garre, M. Gutiérrez-Pimentel, M. Calleja-Hernández (2014)
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithmPharmacogenetics and Genomics, 24
U. Schwarz, M. Ritchie, Y. Bradford, Chun Li, S. Dudek, Amy Frye-Anderson, R. Kim, D. Roden, C. Stein, F.-A (2008)
Genetic determinants of response to warfarin during initial anticoagulation.The New England journal of medicine, 358 10
T. Verhoef, W. Redekop, A. Daly, R. Schie, A. Boer, A. Zee (2014)
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.British journal of clinical pharmacology, 77 4
S. Scott, Rame Khasawneh, I. Peter, R. Kornreich, R. Desnick (2010)
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.Pharmacogenomics, 11 6
P. Wijnen, C. Linssen, G. Haenen, O. Bekers, M. Drent (2012)
Variant VKORC1 and CYP2C9 Alleles in Patients with Diffuse Alveolar Hemorrhage Caused by Oral AnticoagulantsMolecular Diagnosis & Therapy, 14
N Engl J Med, 369
T. Verhoef, G. Ragia, A. Boer, R. Barallon, G. Kolovou, V. Kolovou, S. Konstantinides, S. Cessie, E. Maltezos, F. Meer, W. Redekop, M. Remkes, F. Rosendaal, R. Schie, A. Tavridou, D. Tziakas, M. Wadelius, V. Manolopoulos, A. Zee (2013)
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.The New England journal of medicine, 369 24
V. Pérez-Andreu, V. Roldán, A. Antón, N. García-Barberá, J. Corral, V. Vicente, R. González-Conejero (2009)
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.Blood, 113 20
R. Nahar, R. Saxena, R. Deb, R. Parakh, S. Shad, P. Sethi, Parul Takkar, I. Verma (2014)
CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: Influence on quality of long-term anticoagulationPharmacological Reports, 66
Kostas Arvanitidis, G. Ragia, M. Iordanidou, Sofia Kyriaki, Athanasia Xanthi, A. Tavridou, V. Manolopoulos (2007)
Genetic polymorphisms of drug‐metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek populationFundamental & Clinical Pharmacology, 21
R. Schie, A. Aoussar, F. Meer, A. Boer, A. Zee (2013)
Evaluation of the effects of single‐nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance dosesJournal of Thrombosis and Haemostasis, 11
M. Caldwell, Tarif Awad, Julie Johnson, B. Gage, M. Falkowski, Paul Gardina, J. Hubbard, Y. Turpaz, T. Langaee, C. Eby, Cristi King, Amy Brower, J. Schmelzer, I. Glurich, H. Vidaillet, S. Yale, Kai Zhang, Richard Berg, J. Burmester (2008)
CYP4F2 genetic variant alters required warfarin dose.Blood, 111 8
A. James, R. Britt, C. Raskino, S. Thompson (1992)
Factors affecting the maintenance dose of warfarin.Journal of Clinical Pathology, 45
(2010)
bined CYP 2 C 9 , VKORC 1 and CYP 4 F 2 frequencies among racial and ethnic groups
V. Pérez-Andreu, V. Roldán, M. López-Fernández, A. Antón, I. Alberca, J. Corral, R. Montes, N. García-Barberá, F. Ferrando, V. Vicente, R. González-Conejero (2010)
Pharmacogenetics of acenocoumarol in patients with extreme dose requirementsJournal of Thrombosis and Haemostasis, 8
E. Jiménez-Varo, M. Cañadas-Garre, Cristina Henriques, Ana Pinheiro, M. Gutiérrez-Pimentel, M. Calleja-Hernández (2014)
Pharmacogenetics role in the safety of acenocoumarol therapyThrombosis and Haemostasis, 112
R. Schie, M. Wadelius, F. Kamali, A. Daly, V. Manolopoulos, Anthonius Boer, R. Barallon, T. Verhoef, J. Kirchheiner, E. Haschke-Becher, M. Briz, F. Rosendaal, W. Redekop, M. Pirmohamed, Anke Zee (2009)
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Pharmacogenomics, 10 10
K. Lund, H. Bissett, R. Tait (2014)
Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: reply.Journal of Thrombosis and Haemostasis, 12
J. Cerezo-Manchado, V. Roldán, M. Rosafalco, A. Antón, A. Arroyo, N. García-Barberá, A. Martínez, J. Padilla, J. Corral, V. Vicente, R. González-Conejero (2014)
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.Pharmacogenomics, 15 7
G. Ragia, E. Giannakopoulou, M. Karaglani, Ioanna Karantza, A. Tavridou, V. Manolopoulos (2014)
Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significanceDrug Metabolism and Drug Interactions, 29
F. Takeuchi, R. McGinnis, Stephane Bourgeois, Chris Barnes, N. Eriksson, N. Soranzo, P. Whittaker, V. Ranganath, Vasudev Kumanduri, W. McLaren, Lennart Holm, J. Lindh, A. Rane, M. Wadelius, P. Deloukas (2014)
Supplementary Figure 2
M. Teichert, M. Eijgelsheim, F. Rivadeneira, A. Uitterlinden, R. Schaik, A. Hofman, P. Smet, T. Gelder, L. Visser, B. Stricker (2009)
A genome-wide association study of acenocoumarol maintenance dosage.Human molecular genetics, 18 19
A. Tavridou, I. Petridis, Michail Vasileiadis, G. Ragia, I. Heliopoulos, V. Vargemezis, V. Manolopoulos (2011)
Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus.Diabetes research and clinical practice, 94 2
A. Borobia, R. Lubomirov, E. Ramírez, A. Lorenzo, Armando Campos, R. Muñoz-Romo, C. Fernández‐Capitán, J. Frías, A. Carcas (2012)
An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic DiseasePLoS ONE, 7
H. Thijssen, J. Flinois, P. Beaune (2000)
Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.Drug metabolism and disposition: the biological fate of chemicals, 28 11
G. Ragia, Kostas Arvanitidis, A. Tavridou, V. Manolopoulos (2009)
Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.Pharmacogenomics, 10 1
G. Ragia, S. Marousi, J. Ellul, V. Manolopoulos, A. Tavridou (2013)
Association of Functional VKORC1 Promoter Polymorphism with Occurrence and Clinical Aspects of Ischemic Stroke in a Greek PopulationDisease markers, 35
AbstractBackground:We have earlier developed a pharmacogenomic algorithm for acenocoumarol dose prediction in Greek patients that included CYP2C9/VKORC1 genetic information. This study aims at analyzing the potential effect of CYP4F2, CYP2C19, and CYP1A2 gene polymorphisms on acenocoumarol dose requirements and at further improving the Greek-specific pharmacogenomic algorithm.Methods:A total of 205 Greek patients taking acenocoumarol (140 who reached and 65 who did not reach stable dose), participants of acenocoumarol EU-PACT trial, were included in the study. CYP4F2, CYP2C19, and CYP1A2 polymorphisms were genotyped by use of the PCR-RFLP method. All patients were previously genotyped for CYP2C9/VKORC1 polymorphisms.Results:In the pooled sample, CYP4F2, CYP2C19, and CYP1A2 polymorphisms do not affect independently acenocoumarol dose requirements. For CYP4F2, significant effects were found on patients’ ability to reach stable dose and on acenocoumarol dose requirements when CYP2C9/VKORC1 sub-phenotypes were analyzed. Specifically, when the patients were stratified according to their CYP2C9/VKORC1 functional bins, in sensitive responders, CYP4F2*3 allele carriers (CYP4F2 *1/*3 and *3/*3 genotypes) were more frequent in the patient group who reached stable dose (p=0.049). Additionally, in CYP2C9 intermediate metabolizers (IMs), after adjusting for age, weight, and VKORC1 genotypes, CYP4F2 genotypes were significantly associated with acenocoumarol stable dose (β: 0.07; 95% CI: 0.006–0.134; p=0.033).Conclusions:CYP4F2 gene shows a prominent weak association with acenocoumarol dose requirements. Sub-phenotype analysis is potentially important in determining additional gene polymorphisms that are associated with acenocoumarol dose requirements.
Drug Metabolism and Drug Interactions – de Gruyter
Published: Dec 20, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.